These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 19625083)
1. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN). Kodali S; Chen C; Rathnasabapathy C; Wang JC Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083 [TBL] [Abstract][Full Text] [Related]
2. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders. Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006 [TBL] [Abstract][Full Text] [Related]
3. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377 [TBL] [Abstract][Full Text] [Related]
4. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519 [TBL] [Abstract][Full Text] [Related]
5. No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder. Stijnis C; Kroes WG; Balkassmi S; Marijt EW; van Rossum AP; Bakker E; Vlasveld LT Acta Haematol; 2012; 128(3):183-6. PubMed ID: 22890406 [TBL] [Abstract][Full Text] [Related]
7. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation. Mercier F; Monczak Y; François M; Prchal J; Galipeau J Exp Hematol; 2009 Mar; 37(3):416-20. PubMed ID: 19135773 [TBL] [Abstract][Full Text] [Related]
8. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis. Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884 [TBL] [Abstract][Full Text] [Related]
9. B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Hussein K; Brakensiek K; Ballmaier M; Bormann M; Göhring G; Buhr T; Bock O; Kreipe H Eur J Haematol; 2006 Dec; 77(6):539-41. PubMed ID: 17105449 [No Abstract] [Full Text] [Related]
11. Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm. Eskazan AE; Salihoglu A; Diz-Kucukkaya R; Hancer VS; Soysal T Ann Hematol; 2012 Feb; 91(2):305-6. PubMed ID: 21584669 [No Abstract] [Full Text] [Related]
12. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia. He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074 [TBL] [Abstract][Full Text] [Related]
13. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications. Panani AD Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737 [TBL] [Abstract][Full Text] [Related]
14. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation. Er TK; Lin SF; Chang JG; Hsieh LL; Lin SK; Wang LH; Lin CW; Chang CS; Liu TC Clin Chim Acta; 2009 Oct; 408(1-2):39-44. PubMed ID: 19595684 [TBL] [Abstract][Full Text] [Related]
15. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676 [TBL] [Abstract][Full Text] [Related]
17. A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease. Roug AS; Nyvold CG; Juhl-Christensen C; Christensen M; Schnittger S; Hokland P Eur J Haematol; 2011 Nov; 87(5):461-3. PubMed ID: 21689158 [TBL] [Abstract][Full Text] [Related]
18. A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Koren-Michowitz M; Shimoni A; Vivante A; Trakhtenbrot L; Rechavi G; Amariglio N; Loewenthal R; Nagler A; Cohen Y Leuk Res; 2008 Mar; 32(3):421-7. PubMed ID: 17698191 [TBL] [Abstract][Full Text] [Related]
19. Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue. Salmoiraghi S; Montalvo ML; D'Agostini E; Amicarelli G; Minnucci G; Spinelli O; Rambaldi A Expert Rev Hematol; 2013 Aug; 6(4):429-39. PubMed ID: 23991929 [TBL] [Abstract][Full Text] [Related]
20. JAK2 V617F positive essential thrombocythemia developing in a patient with CD5⁻ chronic lymphocytic leukemia. Wei J; Wang C; Qin YW; Zhu J; Gao YR; Cai Q; Yan SK Chin Med J (Engl); 2012 Jun; 125(11):2076-9. PubMed ID: 22884083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]